Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received an equity compensation award. On August 7, 2026, he acquired 146,909 shares of common stock through a grant of fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. Following this award, he holds 1,434,679 shares of common stock directly.
MYOMO, INC. Chief Financial Officer David A. Henry reported equity compensation activity on August 7, 2026. He received a grant of 68,644 shares of Common Stock via fully vested Restricted Stock Units as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 25,310 shares of Common Stock were withheld at $1.42 per share to pay associated income and other taxes related to this RSU vesting.
Myomo, Inc. reported higher revenue and improved margins for the quarter ended June 30, 2026. Revenue grew to $11.7 million from $9.7 million a year earlier, and six‑month revenue rose to $21.8 million from $19.5 million. Gross margin expanded to 72.1% from 62.7% as higher average selling prices and manufacturing efficiencies outweighed increased clinical costs.
Operating expenses were essentially flat at $10.7 million for the quarter, with lower research and development spending and slightly higher general and administrative costs. Operating loss narrowed to $2.3 million from $4.6 million, and net loss improved to $4.0 million, or $0.09 per share, from $4.6 million, or $0.11 per share. For the first half, net loss was $7.0 million versus $8.1 million, while Adjusted EBITDA loss improved to $3.1 million from $6.8 million.
Cash, cash equivalents and short‑term investments totaled $13.5 million at June 30, 2026, with working capital of $13.9 million and operating cash use reduced to $4.1 million in the first half from $11.5 million a year earlier. A $17.5 million term‑loan facility with Avenue adds committed capital but increases interest expense and introduces derivative‑related fair value volatility, and carries covenants on minimum cash, revenue and cash burn. Revenue is driven mainly by direct billing to patients, U.S. and international O&P channels and the MyoConnect referral program, and remains highly dependent on Medicare and other insurance reimbursement, including updated CMS fee schedules for MyoPro devices.
Myomo, Inc. reported second quarter 2026 revenue of $11.7 million, a 21% increase from a year earlier, driven by higher average selling prices and 211 MyoPro units recognized. Gross margin rose to 72.1% from 62.7% as cost reductions and pricing offset higher clinical costs.
Operating expenses were $10.7 million, up less than 1%, leading to an operating loss of $2.3 million versus $4.6 million last year. Net loss was $4.0 million, or $0.09 per share, including a $1.2 million non-cash derivative liability charge, while Adjusted EBITDA loss improved to $0.8 million from $4.0 million. Cash, cash equivalents and short-term investments totaled $13.5 million, with cash used in operating activities reduced to $1.9 million from $8.9 million. Management now expects third quarter 2026 revenue of $11.5 million to $12.0 million and has raised full-year 2026 revenue guidance to $45 million to $47 million, while reiterating expectations for operating leverage and lower second-half cash burn.
Myomo, Inc. Chief Financial Officer David A. Henry reported compensation-related equity transactions in Myomo common stock. On July 10, 2026, he received a grant of 7,840 Restricted Stock Units under a Board-approved program allowing employees to exchange 10% of salary for RSUs, with a grant date fair value of 115% of the salary exchanged; this grant covers three months of salary and vests in full on October 10, 2026. On July 13, 2026, 5,166 shares were disposed of solely to cover income taxes from RSU vesting, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, Henry holds 426,829 shares of Myomo common stock directly.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. Chief Executive Officer Paul R. Gudonis received a grant of 10,454 Restricted Stock Units as equity compensation. The grant is part of a program allowing employees to exchange 10% of salary for RSUs with a grant date fair value of 115% of the salary exchanged, covering three months of salary. These RSUs vest in full on October 10, 2026. Following this grant, Gudonis directly holds 1,287,770 shares of common stock.
Myomo, Inc. insider David Henry filed to sell shares of the company’s common stock. The planned sale involves 5,166 shares to be executed through Morgan Stanley, related to the vesting of Restricted Stock Units on July 9, 2026 covering 12,500 shares. In the prior three months, Henry sold 3,953 shares of Myomo common stock on April 13, 2026 for total proceeds of $2,806.60.
Myomo, Inc. filed an amended current report to correct exhibit labels and hyperlinks in a prior 8-K, with no changes to the underlying actions. At the June 25, 2026 Annual Meeting, stockholders approved an amendment to the 2018 Stock Option and Incentive Plan, increasing shares available under the plan by 1,833,000.
Stockholders also approved a Charter Amendment increasing authorized common stock to 100,000,000 shares, which became effective upon filing with Delaware on June 25, 2026. As of April 29, 2026, 38,638,669 common shares were outstanding and entitled to vote. All proposals on the agenda, including director elections, executive compensation on an advisory basis, auditor ratification, a stockholder proposal on director classification, and the ability to adjourn the meeting, received the requisite support.
MYOMO, INC. director Joseph M. Manko Jr. reported an acquisition of 78,704 shares of Common Stock as a grant or award. The transaction was recorded at a price of $0.00 per share, and his direct holdings after the transaction total 78,704 shares.
A footnote states he elected to defer receipt of the common stock issuable upon vesting of the related RSUs until the earlier of 30 days after termination of service or a change in control.
Crowley Thomas Aloysius Jr. reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director Thomas Aloysius Crowley Jr. received a grant of 78,704 Restricted Stock Units, each representing one share of common stock, at no cash cost. These RSUs vest in four equal quarterly installments beginning on September 9, 2026. Following this award, he directly holds 154,452 shares.